: Why isn't Imiquimod Cream 5% recommended for the treatment of superficial basal cell carcinoma located on the face? I read on Approval Package for Imiquimod Cream, 5% on February 25, 2010 (mirror): Reference Drug (NDA number):

Vote Up Vote Down   0 Reactions

Login to give Reaction!

Why isn't Imiquimod Cream 5% recommended for the treatment of superficial basal cell carcinoma located on the face?
I read on Approval Package for Imiquimod Cream, 5% on February 25, 2010 (mirror):

Reference Drug (NDA number): Aldara® (imiquimod) 5% Cream (NDA 20-723), Graceway
Pharmaceuticals. Date of approval: 2/27/97
Approved indication(s) based on label approved on 3/22/07: For the topical treatment of:

clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face
or scalp in immunocompetent adults,
biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent
adults; maximum tumor diameter of 2.0 cm on trunk, neck, or extremities (excluding
hands and feet), only when surgical methods are medically less appropriate and patient
follow-up can be reasonably assured.

Why isn't Imiquimod Cream 5% recommended for the treatment of superficial basal cell carcinoma located on the face?

(0)

Login to post a comment!